Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome
Novartis announced today that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted against approval for RLX030 (serelaxin) for the treatment of acute heart failure (AHF).[1] Data presented at […]
